In AT9, we suggested that if a decision was made to use extended treatment of VTE, the same anticoagulant should be used as was used for the initial treatment period. Our intention then was to indicate that there was no obligation to switch from one anticoagulant to a different one after 3 or 6 months of treatment (eg, from LMWH to VKA in patients with VTE and cancer). We have revised the wording of this recommendation to make it clearer that we neither encourage nor discourage use of the same anticoagulant for initial and extended therapy. Although we anticipate that the anticoagulant that was used for initial treatment will often also be used for the extended therapy, if there are reasons to change the type of anticoagulant, this should be done. We also note that whereas apixaban 5 mg twice daily is used for long-term treatment, apixaban 2.5 mg twice daily is used for extended therapy.48 TABLE 5 ] Summary of Findings: Edoxaban vs VKA for Acute and Long-Term Treatment of VTEa,b Outcomes No. of Participants (Studies) Quality of the Evidence (GRADE) Relative Effect Anticipated Absolute Effects Risk with VKA Risk Difference with Edoxaban (95% CI) All-cause mortality Moderatec because of imprecision (from 6 fewer to 10 more) Recurrent VTE 8,240 Moderatec,d because of imprecision (from 15 fewer to 7 more) Major bleeding 8,240 Moderated because of imprecision (from 6 fewer to 3 more) The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). See Table 1 and 4 legends for expansion of abbreviations and GRADE Working Group grades of evidence. 